Filing Analysis
📢 Regulation FD Disclosure
Filed May 13, 2026
⚪ LOW
Eledon Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued and the 8-K was filed on May 13, 2026.
- The document was signed by CEO David-Alexandre C. Gros, M.D.
📢 Regulation FD Disclosure
Filed Mar 19, 2026
⚪ LOW
Eledon Pharmaceuticals, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release on March 19, 2026.
📋 Key Facts
- The company reported financial results for the quarter and year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued on March 19, 2026, and is attached as Exhibit 99.1.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.